Report #2826907

Received Feb 18, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 60 yrs
State: KS
Recovered: Unknown
Vaccinated: Jan 30, 2025
Onset: Jan 30, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
TDAP	TDAP (BOOSTRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	M77CC	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Patient received a second dose of Boostrix too early; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 60-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number M77CC, expiry date 19-MAR-2027) for prophylaxis. Previously administered products included Boostrix (received 1st dose on 13-JAN-2020). On 30-JAN-2025, the patient received the 2nd dose of Boostrix. On 30-JAN-2025, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: Patient received a second dose of Boostrix too early). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 03-FEB-2025 The patient had received a second dose of Boostrix too early, which led to an extra dose administered.